WO3970 clinical trials
Also written WO3970.
How each study uses WO3970 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- WO3970
- 3
Studies by the year they started
3 studies that test it; most in 2016 (1)
| Year | Studies |
|---|---|
| 2016 | 1 |
| 2018 | 1 |
| 2019 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 3 · Other 0
Dr. August Wolff GmbH & Co. KG Arzneimittel (3)
Often tested with
Tested in the same studies.
WO3979 (1) · WO3992 (1)
Studies
Open first, then newest update. How each study uses WO3970 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- Assessment of Safety, Tolerability and Efficacy of 1% GPB Cream Versus Qbrexza® (Glycopyrronium) Cloth 2.4% Under Maximum-Use Conditions in Subjects with Primary Axillary HyperhidrosisWithdrawnPhase 2Dr. August Wolff GmbH & Co. KG ArzneimittelNCT04159610Written as WO3970
- Assessment of Efficacy and Safety of Topical Administration of 1% Glycopyrronium Bromide (GPB) in Patients With Primary Axillary Hyperhidrosis and the Assessment of Long-term Efficacy and Safety of Topical Administration of 1% GPB Cream in Patients With Primary Axillary Hyperhidrosis.CompletedPhase 3Dr. August Wolff GmbH & Co. KG ArzneimittelNCT03658616Written as WO3970
- Investigation of Ascending Concentrations of Glycopyrronium Bromide (GPB) in a Topical Formulation in Subjects With Axillary HyperhidrosisCompletedPhase 1Dr. August Wolff GmbH & Co. KG ArzneimittelNCT03037788Written as WO3970